---
title: "Titan Biotech Ltd (524717) — Share Price, Financials & Analysis"
symbol: "524717"
company: "Titan Biotech Ltd"
canonical: "https://tapetide.com/stocks/524717"
isin: "INE150C01029"
nse_symbol: "TITANBIOTECHLTD"
bse_code: "524717"
sector: "Chemicals"
industry: "Specialty Chemicals"
market_cap_cr: 1771.37
generated_at: "2026-09-13T19:16:27.491Z"
---

# Titan Biotech Ltd (524717)

Canonical page: https://tapetide.com/stocks/524717

## Company

- **NSE Symbol:** TITANBIOTECHLTD
- **BSE Code:** 524717
- **ISIN:** INE150C01029
- **Sector:** Chemicals
- **Industry:** Specialty Chemicals
- **Macro Sector:** Commodities
- **Stock Type:** EQUITY
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** titanbiotechltd.com

## About

Incorporated in 1992, Titan Biotech 
Ltd manufacturer and exporter of 
the Biological products[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:43:01.133390Z.

- **Market Cap:** ₹1771.37 Cr
- **Classification:** Microcap
- **P/E (reported):** 53
- **EPS (TTM):** ₹8.21
- **EPS (reported):** ₹30.36
- **Book Value:** ₹43.94
- **Price to Book:** 9.88
- **Dividend Yield:** 0.12%
- **ROE:** 11.91%
- **ROCE:** 16.03%
- **Debt to Equity:** 0.03
- **Revenue (yearly):** ₹206.19 Cr
- **Net Income:** ₹28.28 Cr
- **EBITDA:** ₹38.6 Cr
- **52-Week High:** ₹555.65
- **52-Week Low:** ₹132.04
- **RSI (14):** 61.16

## Tapetide Score

- **Score:** 60 / 100
- **Score date:** 2026-09-04
- **Archetype:** Priced for Perfection
- **What it means:** The business scores well but the multiple leaves little room for error. The debate here is about the price, not the company; small disappointments tend to cost more at rich valuations.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Rising
- **Percentile:** 87.9 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 90.03 | 9% |
| growth | 93.89 | 9% |
| momentum | 89.49 | 12% |
| ownership | 45.52 | 24% |
| quality | 81.02 | 22% |
| valuation | 20.42 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company is expected to give good quarter

### Weaknesses

- Stock is trading at 9.95 times its book value
- The company has delivered a poor sales growth of 7.71% over past five years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -4.87% | -5% | 5.45% |
| ebitda margin growth | 21.19% | -0.33% | -16.06% | -29.49% |
| net income growth | 62.69% | 54.54% | 6% | 0% |
| revenue growth | 19.84% | 28.55% | 13% | 8% |
| roce | 22.91% | -32.62% | -36.59% | 30.47% |
| roe | 61.37% | -32.83% | 16.26% | -72.78% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 43 | 46 | 40 | 43 | 40 | 38 | 35 | 46 | 54 | 57 | 49 | 59 |
| Expenses | 35 | 35 | 33 | 35 | 32 | 33 | 31 | 38 | 45 | 46 | 39 | 47 |
| Operating Profit | 9 | 11 | 7 | 8 | 8 | 5 | 5 | 9 | 9 | 11 | 10 | 12 |
| OPM % | 20 | 23 | 18 | 19 | 19 | 13 | 13 | 19 | 17 | 19 | 20 | 21 |
| Other Income | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 8 | 10 | 6 | 8 | 7 | 5 | 5 | 8 | 9 | 11 | 10 | 13 |
| Tax % | 26 | 26 | 24 | 24 | 25 | 26 | 25 | 24 | 26 | 26 | 36 | 26 |
| Net Profit | 7 | 7 | 5 | 6 | 7 | 4 | 4 | 7 | 8 | 9 | 7 | 11 |
| EPS in Rs | 1.58 | 1.74 | 1.21 | 1.55 | 1.62 | 1.06 | 0.98 | 1.66 | 1.88 | 2.07 | 1.63 | 2.63 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 57 | 65 | 79 | 142 | 124 | 144 | 164 | 156 | 206 | 219 |
| Expenses | 50 | 56 | 66 | 96 | 92 | 114 | 130 | 131 | 168 | 176 |
| Operating Profit | 7 | 9 | 13 | 46 | 31 | 30 | 34 | 25 | 39 | 42 |
| OPM % | 12 | 14 | 17 | 32 | 25 | 21 | 21 | 16 | 19 | 19 |
| Other Income | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 4 | 5 | 6 |
| Interest | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 5 | 5 |
| Profit before tax | 4 | 6 | 10 | 43 | 29 | 28 | 32 | 24 | 38 | 43 |
| Tax % | 35 | 30 | 25 | 26 | 25 | 25 | 25 | 25 | 28 | — |
| Net Profit | 3 | 4 | 8 | 32 | 22 | 25 | 25 | 22 | 30 | 34 |
| EPS in Rs | 0.66 | 0.85 | 1.71 | 7.35 | 5.25 | 6.01 | 6.02 | 5.21 | 7.23 | 8.21 |
| Dividend Payout % | 23 | 0 | 12 | 4 | 6 | 6 | 7 | 8 | 7 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 15 | 17 | 24 | 31 | 60 | 78 | 102 | 125 | 145 | 173 |
| Borrowings | 22 | 26 | 24 | 24 | 16 | 9 | 9 | 8 | 3 | 6 |
| Other Liabilities | 7 | 7 | 9 | 13 | 16 | 13 | 16 | 15 | 19 | 27 |
| Total Liabilities | 52 | 57 | 65 | 76 | 101 | 108 | 135 | 157 | 175 | 214 |
| Fixed Assets | 13 | 14 | 29 | 31 | 34 | 35 | 36 | 52 | 57 | 62 |
| CWIP | 9 | 13 | 0 | 0 | 0 | 4 | 13 | 3 | 2 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 4 | 15 | 28 | 33 | 60 |
| Other Assets | 30 | 30 | 36 | 45 | 67 | 65 | 70 | 74 | 83 | 90 |
| Total Assets | 52 | 57 | 65 | 76 | 101 | 108 | 135 | 157 | 175 | 214 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 2 | 5 | 6 | 19 | 22 | 21 | 21 | 20 | 30 |
| Cash from Investing Activity | -8 | -6 | -4 | -2 | -5 | -16 | -21 | -20 | -10 | -34 |
| Cash from Financing Activity | 9 | 0 | 0 | -4 | -11 | -4 | -2 | -3 | -8 | 0 |
| Net Cash Flow | 1 | -3 | 1 | 0 | 4 | 2 | -2 | -2 | 2 | -4 |
| Free Cash Flow | -7 | -4 | 1 | 8 | 14 | 8 | 8 | 12 | 12 | 21 |
| CFO/OP | 21 | 43 | 74 | 62 | 65 | 93 | 97 | 85 | 103 | 101 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 44 | 49 | 52 | 54 | 46 | 48 | 53 | 42 | 44 | 40 |
| Inventory Days | 155 | 202 | 236 | 259 | 177 | 206 | 179 | 208 | 242 | 212 |
| Days Payable | 15 | 13 | 24 | 38 | 20 | 25 | 27 | 15 | 25 | 32 |
| Cash Conversion Cycle | 184 | 239 | 264 | 276 | 203 | 230 | 205 | 234 | 261 | 220 |
| Working Capital Days | 90 | 108 | 97 | 101 | 88 | 118 | 109 | 111 | 130 | 102 |
| ROCE % | 12 | 13 | 15 | 20 | 58 | 32 | 27 | 25 | 17 | 23 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 55.88% | 55.88% | 55.88% | 55.88% | 55.88% | 55.88% | 55.88% | 55.88% | 55.78% | 55.78% | 55.78% | 55.78% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0.23% | 0% | 0% | 0% | 0.01% | 0.03% | 0.03% | 0.03% | 0.03% | 0.01% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 31.44% | 30.12% | 30.06% | 30.11% | 29.97% | 29.43% | 29.2% | 29.44% | 29.65% | 29.74% | 27.72% | 28.02% |
| Others | 12.68% | 14% | 13.84% | 14.01% | 14.15% | 14.69% | 14.91% | 14.65% | 14.54% | 14.45% | 16.47% | 16.19% |
| No. of Shareholders | 17455 | 15756 | 15876 | 15850 | 15700 | 16038 | 16370 | 16328 | 16040 | 16367 | 17457 | 18671 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 4 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 416.26 | Buy |
| EMA (10) | 418.01 | Buy |
| SMA (20) | 403.72 | Buy |
| EMA (20) | 410.83 | Buy |
| SMA (50) | 407.33 | Buy |
| EMA (50) | 409.49 | Buy |
| SMA (100) | 425.78 | Buy |
| EMA (100) | 400.26 | Buy |
| SMA (200) | 350.24 | Buy |
| EMA (200) | 351.88 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 61.26 | Neutral |
| MACD (12,26,9) | 6.31 | Buy |
| Stochastic (14,3,3) | 83.46 | Sell |
| ADX (14) | 18.04 | Neutral |
| Williams %R (14) | -7.7 | Sell |
| ATR (14) | 20.98 | High Volatility |
| ROC (12) | 15.42 | Buy |
| Stoch RSI (14) | 84.58 | Sell |
| UO (7,14,28) | 63.15 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea824dc4-4fc4-49e2-957e-6af4cd2d8fdf.pdf) |
| 2026-09-07 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a29048d-4f88-49f8-81e9-dae1f3b00bcd.pdf) |
| 2026-09-05 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b02e902-60b0-4b4f-8efe-ca5eda51f0b4.pdf) |
| 2026-09-05 | [Notice Of Thirty- Fourth (34Th) Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=752184f1-8bdc-466f-83c1-587d0dbef5f4.pdf) |
| 2026-09-05 | [Intimation Regarding Weblink To Access The Annual Report For FY 2025-26 And Notice Of The 34Th Annual General Meeting For Shareholders Whose Email Ids Are Not Registered](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=39b3e84d-7938-4d53-b33a-b47c06abded7.pdf) |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b763728d-18e6-4482-b6f3-979829afaaaa.pdf) |
| 2026-09-03 | [Board Meeting Outcome for Outcome Of Board Meeting Dated September 3 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=91baaef7-40be-4ff1-b83e-bef99141a9ec.pdf) |
| 2026-09-03 | [Corporate Action-Board recommends Bonus Issue](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d57fa7b-83a3-4eb9-852d-5cdcbfd47078.pdf) |
| 2026-09-03 | [Corporate Action-Fixes Book Closure For 34Th Annual General Meeting Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d51a9c8e-546e-4fea-9c54-99b744702e0f.pdf) |
| 2026-09-03 | [Fixation Of Annual General Meeting Date Record Date Book Closure Date And E-Voting Date](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca74ce43-b3ec-45fb-a3fa-dddaf97b72c7.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-13 | [Unaudited Financial Results For Quarter Ended June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=53d2c8a6-1477-4be3-ae07-646e8179b993.pdf) |
| 2026-05-30 | [Result_Audited Financial Results For The Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98cdba0e-343c-4796-bb39-e32928aba2f4.pdf) |
| 2026-02-12 | [Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f5f58289-6a47-49da-90f2-85700abdff5e.pdf) |
| 2025-11-11 | [Consolidated And Standalone Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca4bf87d-df88-4bdc-a927-99627fa9fd74.pdf) |
| 2025-08-13 | [Unaudited Financial Results For Quarter Ended June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aa5cb05e-a85a-426b-b094-69afc1810339.pdf) |
| 2025-05-30 | [Results_Audited Financial Results For The Quarter And Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=54fe9ca3-b87d-4a4a-bc2e-35cb20f8f466.pdf) |
| 2025-02-12 | [Unaudited Financial Result For The Quarter And Nine Months Ended On 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9d3a457-917a-49b6-9f80-e138cf8ca930.pdf) |
| 2024-11-12 | [Unaudited Financial Results For 3 Months Ended 30Th September 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca22c771-5494-46ea-b56a-71c81809e80e.pdf) |
| 2024-05-29 | [Audited Results For Quarter And Year Ended 31.03.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12336a82-f930-46bf-811a-7dd47625dd48.pdf) |
| 2024-02-12 | [Unaudited Financial Results For Quarter Ended 31St December 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ec3ac5d-0389-41b2-a541-5214c0929c99.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 6 May - Titan Biotech launches Saksham Niveshak campaign, urging shareholders to update KYC and claim unclaimed dividends by July 9, 2026. | [Intimation Regarding Second 100 Days Campaign - 'Saksham Niveshak' 6 May - Titan Biotech launches Saksham Niveshak campaign, urging shareholders to update KYC and claim unclaimed dividends by July 9, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a0c43607-e751-4697-bb4a-0c05a0849345.pdf) |
| 6 May - Newspaper ads published for one-year special window to re-lodge transfers and dematerialise physical shares. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 May - Newspaper ads published for one-year special window to re-lodge transfers and dematerialise physical shares.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/809458a7-9247-4f8d-953f-75f35d092013.pdf) |
| 6 Jan - Donear confirms MUFG Intime certificate under Reg.74(5) for quarter and nine months ended Dec 31, 2025. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Jan - Donear confirms MUFG Intime certificate under Reg.74(5) for quarter and nine months ended Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5369dc87-30cb-47ce-aedd-f15bd4dccf67.pdf) |
| 6 Feb - Corrigendum to Intimation dated 06th February, 2026 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Feb - Corrigendum to Intimation dated 06th February, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b8f648d6-fddf-4ec6-9ac4-1cef320d5e7f.pdf) |
| 6 Apr - Company issued newspaper advertisement for loss of share certificates. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 Apr - Company issued newspaper advertisement for loss of share certificates.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3a547ce6-4b0f-4a86-9fbb-c7b703388e54.pdf) |
| 4 May - Titan Biotech filed FY2026 annual secretarial compliance report; no major non-compliances reported. | [Compliances-Reg.24(A)-Annual Secretarial Compliance 4 May - Titan Biotech filed FY2026 annual secretarial compliance report; no major non-compliances reported.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7cd30951-7476-49b1-a95f-c43fcd1ad739.pdf) |
| 4 May - Titan Biotech filed FY2026 annual secretarial compliance report; no major non-compliances reported. | [Compliances-Reg.24(A)-Annual Secretarial Compliance 4 May - Titan Biotech filed FY2026 annual secretarial compliance report; no major non-compliances reported.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7cd30951-7476-49b1-a95f-c43fcd1ad739.pdf) |
| 4 Feb - Board meeting Feb 9, 2026 to approve Q3/9M unaudited results ended Dec 31, 2025; trading window closed. | [Board Meeting Intimation for Intimation Of Board Meeting Of Donear Industries Limited To Be Held On Monday, February 09, 2026. 4 Feb - Board meeting Feb 9, 2026 to approve Q3/9M unaudited results ended Dec 31, 2025; trading window closed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d731658a-a7ba-4c9d-8da6-17c16e3a5824.pdf) |
| 28 Apr - Titan Biotech confirms it is not a Large Corporate; outstanding borrowing was nil on 31 March 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 28 Apr - Titan Biotech confirms it is not a Large Corporate; outstanding borrowing was nil on 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/45c103ea-8282-4965-a242-8564055d44c4.pdf) |
| 28 Apr - Titan Biotech confirms it is not a Large Corporate; outstanding borrowing was nil on 31 March 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 28 Apr - Titan Biotech confirms it is not a Large Corporate; outstanding borrowing was nil on 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/45c103ea-8282-4965-a242-8564055d44c4.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2013 from nse](https://archives.nseindia.com/annual_reports/AR_2930_DONEAR_2012_2013_21112013085756.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/69f6aa77-fda0-4fcd-a098-36c155a3b84f.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2179ba8a-bcf3-41c9-8126-f5b42308ce25.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f9a74f63-d46f-4bc9-beb2-bc2a669e6410.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5ad6b711-5332-4023-be0c-c4bd50633f68.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/993bbcda-b226-4caf-bab4-73d8f7bda625.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6d790c3-dab2-4d15-8881-2c7b069b106b.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/512519/74821512519.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524717/75222524717.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/512519/70178512519.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:16:27.491Z.